SpringWorks Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewsWire • 10/08/20
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 10/05/20
SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor ConferenceGlobeNewsWire • 09/22/20
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple MyelomaGlobeNewsWire • 09/18/20
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 09/14/20
SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/12/20
SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/04/20
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid TumorsGlobeNewsWire • 07/22/20
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical TrialGlobeNewsWire • 06/22/20
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 06/22/20
SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% HigherZacks Investment Research • 06/17/20
SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceGlobeNewsWire • 06/02/20
SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of DirectorsGlobeNewsWire • 05/26/20
SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/12/20
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039GlobeNewsWire • 03/18/20
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple MyelomaGlobeNewsWire • 01/13/20
Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) GlobeNewsWire • 12/09/19
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)GlobeNewsWire • 10/24/19
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue SarcomaGlobeNewsWire • 09/24/19
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional SharesGlobeNewsWire • 09/17/19